Vyvanse (Lisdexamfetamine): Mechanism, Dosing, and How to Take It Correctly

Does Vyvanse Come in an Injectable Form?

Vyvanse is approved only as an oral capsule or chewable tablet. No injectable, subcutaneous, intramuscular, or intravenous formulation of lisdexamfetamine exists, and none has received FDA approval as of 2025. The prodrug design is intentional: lisdexamfetamine must pass through the gastrointestinal tract so that peptidase enzymes in red blood cells and intestinal epithelium can cleave the lysine amino acid from the molecule to release active d-amphetamine. Injection of lisdexamfetamine would bypass this conversion step, produce erratic pharmacokinetics, and carries serious cardiovascular risk.

The FDA label explicitly states that Vyvanse capsules may be swallowed whole or opened and dissolved in water before oral ingestion. No other route is approved. [1]

Why the Prodrug Design Blocks Misuse by Injection

The lysine-lisdexamfetamine bond is resistant to rapid hydrolysis outside the GI/bloodstream enzymatic environment. A 2007 pharmacokinetic study published in CNS Drugs confirmed that the conversion to d-amphetamine is rate-limited by enzymatic cleavage, not by absorption speed, which deliberately flattens the concentration-time curve that produces euphoric "rush" when stimulants are injected. [2]

This pharmacokinetic architecture is one reason the Drug Enforcement Administration classifies lisdexamfetamine as Schedule II while its pharmacokinetic profile produces a slower Cmax rise than equivalent oral d-amphetamine salts.

How Vyvanse Works: Mechanism of Action

Step 1, Prodrug Conversion

After swallowing, lisdexamfetamine is absorbed intact from the proximal small intestine. Hydrolysis occurs primarily in red blood cells via erythrocyte peptidases, releasing d-amphetamine and the amino acid L-lysine. Peak plasma d-amphetamine concentrations are reached in approximately 3.8 hours (Tmax) after a 70 mg dose. [2]

Step 2, Monoamine Release and Reuptake Inhibition

D-amphetamine enters presynaptic neurons through the dopamine transporter (DAT) and norepinephrine transporter (NET). Inside the terminal, it reverses vesicular monoamine transporter 2 (VMAT2), flooding the synapse with dopamine and norepinephrine. It also weakly inhibits monoamine oxidase (MAO), slowing dopamine and norepinephrine degradation. [3]

The net result is substantially elevated synaptic dopamine and norepinephrine in prefrontal cortex circuits. These circuits govern working memory, impulse control, and sustained attention, the domains most impaired in ADHD.

Step 3, Duration Advantage Over Immediate-Release Stimulants

Because the prodrug must be enzymatically cleaved first, the d-amphetamine concentration rises more slowly than it does after immediate-release amphetamine. Wigal et al. (J Atten Disord, N=277) demonstrated statistically significant ADHD symptom reduction sustained across a 12-to-13-hour observation window, from 1.5 hours post-dose through the evening, without the abrupt symptom rebound common with shorter-acting agents. [4]

FDA-Approved Indications and Trial Evidence

ADHD in Children, Adolescents, and Adults

The FDA approved Vyvanse for ADHD in 2007 (ages 6 and older) and extended approval to adults based on controlled trial data. A 4-week randomized controlled trial (N=420) in adults showed lisdexamfetamine produced significantly greater reductions in ADHD Rating Scale IV scores versus placebo at doses of 30 mg, 50 mg, and 70 mg (all P<0.001). [5]

The American Academy of Pediatrics 2019 Clinical Practice Guideline recommends stimulant medications as first-line pharmacotherapy for school-age children with ADHD, citing effect sizes of 0.8 to 1.0 for core symptom reduction. [6]

Binge Eating Disorder

Vyvanse is the only FDA-approved pharmacotherapy for moderate-to-severe binge eating disorder (BED) in adults. Two key 12-week randomized trials (BED-1, N=383; BED-2, N=390) showed that lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by approximately 3.9 days versus 1.3 days for placebo (P<0.001). [7]

The FDA approved the BED indication in January 2015, making Vyvanse the first drug with this specific label. [8]

Correct Oral Self-Administration Technique

Standard Capsule Method

1. Take Vyvanse at the same time each morning, with or without food.
2. Swallow the capsule whole with enough water to ensure it reaches the stomach.
3. If swallowing capsules is difficult, open the capsule over a glass and pour the entire powder contents into 4 to 8 ounces of water. Stir until fully dissolved. Drink immediately. Do not store the solution.
4. Never crush or chew the capsule bead contents for inhalation, doing so alters drug delivery and constitutes misuse under the DEA Schedule II framework.

Chewable Tablet Method

The chewable tablet formulation (Vyvanse 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg) must be chewed completely before swallowing. Swallowing it whole does not break the tablet down in the same dissolution pattern as the capsule and could theoretically alter the rate of absorption, though the clinical significance of this difference has not been formally studied.

Timing and Food Interaction

Food delays but does not reduce the total amount of d-amphetamine absorbed. A pharmacokinetic study of Vyvanse 70 mg (N=27 healthy adults) found that a high-fat meal extended Tmax from 3.8 hours to 4.7 hours but did not alter overall AUC or Cmax. [2] Patients who experience nausea with morning dosing may take Vyvanse with food without loss of efficacy.

Taking the dose after noon increases the risk of insomnia. Most prescribers instruct patients to dose between 6:00 AM and 9:00 AM.

Missed Dose Protocol

Skip the missed dose if it is already afternoon. Never double-dose. The half-life of d-amphetamine derived from lisdexamfetamine is approximately 10 to 13 hours, meaning an afternoon dose extends active drug exposure well into sleeping hours.

Dosing: Starting, Titration, and Maximum

ADHD Dosing Schedule

| Patient Group | Starting Dose | Titration | Maximum Dose | |---|---|---|---| | Children 6 to 12 | 20 mg, 30 mg once daily | Increase by 10 to 20 mg/week | 70 mg/day | | Adolescents 13 to 17 | 30 mg once daily | Increase by 10 to 20 mg/week | 70 mg/day | | Adults 18+ | 30 mg once daily | Increase by 10 to 20 mg/week | 70 mg/day |

The FDA label does not establish a weight-based dosing recommendation. Clinical response and tolerability guide titration more than body mass. [9]

BED Dosing Schedule

The approved BED starting dose is 30 mg/day for the first week, then 50 mg/day in week 2. The target dose range is 50 to 70 mg/day. The minimum effective dose shown in the key trials was 50 mg. Doses below 50 mg have not demonstrated statistically significant separation from placebo for BED. [7]

Renal Impairment Adjustments

Lisdexamfetamine itself is renally cleared. The FDA label specifies:

• Moderate renal impairment (GFR 30 to 59 mL/min/1.73 m²): maximum dose 50 mg/day
• Severe renal impairment (GFR 15 to 29 mL/min/1.73 m²): maximum dose 30 mg/day
• End-stage renal disease (GFR <15 mL/min/1.73 m²): do not use [9]

Monitoring and Safety Considerations

Cardiovascular Monitoring

Amphetamines increase heart rate and blood pressure. A meta-analysis of 21 randomized trials (N=2,971 pediatric and adult patients) found that stimulant medications raised mean systolic blood pressure by 1 to 4 mmHg and heart rate by 3 to 6 beats per minute compared to placebo. [10]

The American Heart Association recommends obtaining a personal and family cardiovascular history plus resting blood pressure and heart rate before initiating any stimulant. Patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmia should not receive Vyvanse. [11]

Growth Monitoring in Pediatric Patients

Long-term stimulant use in children is associated with modest height velocity suppression during active treatment. A study in Pediatrics (N=579, 3-year follow-up) found that children treated continuously with mixed amphetamine salts showed a mean 1.4 cm reduction in expected height at 3 years compared to untreated controls, with attenuation of the effect after year 2. [12]

Prescribers should plot height and weight on growth charts at every visit during pediatric Vyvanse treatment.

Psychiatric Monitoring

New or worsening psychosis, aggression, or mania can emerge with stimulant use even in patients without a prior psychiatric diagnosis. The FDA label for Vyvanse carries a warning that prescribers should evaluate for bipolar disorder before starting the drug, since stimulants may trigger manic episodes in undiagnosed patients. [9]

Substance Use Considerations

Vyvanse is a DEA Schedule II controlled substance. Prescriptions cannot be refilled and require a new written or electronic prescription each month. The FDA Prescription Drug Monitoring Program guidance recommends that prescribers check state PDMP databases before writing each prescription for a Schedule II stimulant. [13]

Drug Interactions Clinically Relevant to Patients

MAO Inhibitors

Combining Vyvanse with any MAO inhibitor (phenelzine, tranylcypromine, selegiline, linezolid) risks hypertensive crisis. The FDA label mandates a 14-day washout from any MAOI before starting lisdexamfetamine. [9]

Acidifying Agents

Urinary acidifiers (ammonium chloride, sodium acid phosphate) lower urine pH, which increases renal tubular reabsorption of amphetamine. This extends the half-life and can push exposure above expected therapeutic levels. Ascorbic acid in high doses carries the same risk.

Alkalinizing Agents

Antacids containing sodium bicarbonate raise urine pH and increase amphetamine excretion, potentially reducing efficacy. Patients taking high-dose antacids regularly should be monitored for diminished clinical response.

Serotonergic Agents

Co-administration with serotonergic drugs (SSRIs, SNRIs, triptans, tramadol) warrants monitoring for serotonin syndrome, a potentially life-threatening condition marked by hyperthermia, clonus, and agitation. [14]

What Patients Often Ask About Vyvanse Administration

The HealthRX clinical team has identified a pattern in patient queries about Vyvanse administration. Three misconceptions arise frequently enough to warrant a structured clinical response framework.

Misconception 1: "Opening the capsule and dissolving it reduces efficacy." It does not. The FDA label explicitly permits this method. The bioavailability of d-amphetamine from dissolved powder in water is equivalent to swallowing the intact capsule, confirmed in the pharmacokinetic study cited above. [2]

Misconception 2: "Taking Vyvanse with coffee cancels it out." Caffeine and amphetamine act through different mechanisms. Caffeine inhibits adenosine receptors; amphetamine promotes monoamine release. No pharmacokinetic interaction reduces d-amphetamine levels. The two substances do have additive cardiovascular effects (tachycardia, blood pressure elevation), which some patients find uncomfortable. That is a reason for caution, not a pharmacokinetic cancellation.

Misconception 3: "Splitting the dose across morning and midday gives smoother coverage." The prodrug design already produces gradual, sustained d-amphetamine release. Splitting a single daily dose into two administrations is off-label, introduces an afternoon dose that may impair sleep, and is not supported by published pharmacokinetic data. Wigal et al. Confirmed that a single morning dose maintained therapeutic effect through evening hours without requiring supplemental dosing. [4]

Vyvanse Versus Other Long-Acting Stimulants

| Medication | Prodrug | Duration | Peak Tmax | Schedule | |---|---|---|---|---| | Vyvanse (lisdexamfetamine) | Yes | 12 to 14 h | ~3.8 h | DEA II | | Adderall XR (mixed amphetamine salts ER) | No | 8 to 12 h | ~7 h (bimodal) | DEA II | | Concerta (methylphenidate OROS) | No | 10 to 12 h | ~6 to 8 h | DEA II | | Ritalin LA (methylphenidate LA) | No | 8 to 10 h | ~4 to 5 h (bimodal) | DEA II | | Mydayis (mixed amphetamine salts ER triple-bead) | No | up to 16 h | ~8 h | DEA II |

The slower Tmax of Vyvanse relative to Adderall XR is a direct consequence of the rate-limiting enzymatic conversion step. [15]

Starting Vyvanse Through a Telehealth Provider

Telehealth prescribing of Schedule II stimulants in the United States was permitted via the DEA's COVID-19 telemedicine flexibilities, but new permanent rules are still being finalized. As of mid-2025, prescribers may issue an initial Vyvanse prescription via telemedicine for patients with a prior in-person ADHD diagnosis on record. New patients without any prior ADHD documentation typically require at least one in-person evaluation under current proposed DEA Special Registration rules. Patients should confirm their telehealth provider's prescribing model before scheduling.